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Abstract
Background: Snakebite is a common neglected public health issue, especially in poor rural areas of sub-Saharan
Africa, Asia and Latin America. Passive immunotherapy with safe and effective antivenom is the only approved
treatment for it. This study aimed to determine the incidence of snakebites, and to assess the availability and
accessibility of antivenoms, from 2010 to 2014, in Burkina Faso.
Methods: The assessment of snakebite cases managed in all health facilities from 2010 to 2014 was performed
from the Statistical Yearbook of the Ministry of Health. Antivenom consumption data were collected from the
drug wholesalers established in Burkina Faso.
Results: Snakebites are among the five leading causes of consultations in health districts. From 2010 to 2014,
114,126 envenomation cases occurred in Burkina Faso, out of which 62,293 (54.6 %) victims have been hospitalized
resulting in 1,362 (2 %) deaths. The annual incidence and mortality were respectively 130 bites and 1.75 deaths per
100,000 inhabitants. The amount of antivenom sold by wholesalers were 5,738 vials with a total cost of US$ 539,055
(annual average = US$ 107,811). The high cost of these antivenoms (between US$ 42 and 170 per dose according to
brand) limited their use by rural people, the main victims of snakebites, whose income is insufficient. Thus, only 4 %
of patients received antivenom treatment over the past five years. The price of antivenom was reduced in 2015 to
US$ 3.4 by a public drug wholesaler.
Conclusion: The study confirmed the high burden of snakebites in Burkina Faso. To better manage envenomation,
Burkina Faso implemented a strategy consisting in seeking affordable sources of antivenom supply of good quality
and innovative mechanisms of subsidy.
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Background
Although snakebite envenomation is considered a par-
ticularly important and frequent public health hazard in
several countries, it remains largely neglected. It affects
mainly rural areas of tropical and subtropical countries,
particularly sub-Saharan Africa where the management
is inefficient. Besides the cost of antivenom, sometimes
equivalent to several months of a family income, the lack
of standardized treatment protocol due to insufficient
training of health personnel as well as underestimation
of the incidence and severity of snakebites make difficult
the implementation of a management strategy both for
prevention and treatment [1].
In Burkina Faso, the different snake species belong to
six families, among which Elapidae and Viperidae are
the most venomous [2]. Passive immunotherapy with
safe and effective animal-derived antivenom is the only
approved treatment. However, its availability is ques-
tioned because of its high cost and poor demand from
victims and health professionals who do not use it [3].
A recent meta-analysis of the literature estimated the
average annual snakebite incidence and mortality in
Burkina Faso, respectively, at 7,341 ± 1,260 envenoma-
tions and 343 ± 73 deaths [4]. Those figures, useful for a
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basic approach to the implementation of snakebite man-
agement in health services, are imprecise and subject to
biases according to the representativeness of the studies
used for the assessment.
Burkina Faso has a pyramidal health system in three
levels with a national health statistic service that pro-
vides centralized epidemiological data. The notification
of snakebites at different levels of the health pyramid is
operational since 2010. We collected data provided by
the Ministry of Health on all patients treated in health
facilities in the country aiming to evaluate the annual
incidence and mortality from snakebites in Burkina
between 2010 and 2014. The present findings may serve
as an indicator to define an appropriate management
strategy. We also evaluated the availability of antivenom
during this period in order to propose some improve-
ments in its accessibility.
Methods
Burkina Faso is divided into 13 health regions.
General population data were provided by the Na-
tional Institute of Statistics and Demography (INSD),
the central organ for official statistics production in
Burkina Faso (http://www.insd.bf/n/). Methods and
results of the last census in 2006 are accessible at http://
www.insd.bf/n/nada/index.php/catalog/23 (in French).
Snakebites treated in health facilities of the country
from 2010 to 2014 have been notified according to
levels of the health pyramid by the Ministry of Health
in the sanitary statistical yearbooks. Some of these
documents are online (http://www.cns.bf/IMG/pdf/an
nuaire_ms_2012.pdf; http://www.cns.bf/IMG/pdf/annu
aire_sante_2013.pdf ), while others are available in the
archives of the Ministry of Health in Ouagadougou,
Burkina Faso.
Each annual report specified the incidence and mortal-
ity of major diseases diagnosed in health facilities of the
country, including snakebites, whose declaration is
mandatory since 2010. The data were presented by gen-
der, age group and geographic regions. Moreover, outpa-
tients (not hospitalized) and patients undergoing a
hospital stay of at least 24 h were presented separately.
The antivenom consumption data were collected
from the main drug wholesalers in the country:
Ubipharm, CAMEG, Laborex, DPD and Tedis Pharma.
Each wholesaler was asked about orders and sales of anti-
venom between 2010 and 2014 and provided the corre-
sponding data.
Statistical tests used were Pearson’s χ2 test with Yates’
continuity correction and the Pearson correlation test.
Excel® statistical tools were used to perform the
analysis. The statistical significance and confidence
intervals were p = 0.05.
Results
Snakebite incidence and mortality
The total number of snakebite cases recorded from 2010
to 2014 was 114,126 with an average annual incidence of
136 ± 9 bites per 100,000 people (Table 1).
Table 2 specifies the number of snakebites treated in
the various health facilities. Outdoor patients corre-
sponded to snakebite victims treated as outpatients and
whose health did not require hospitalization. Hospital-
ized patients were envenomated people that required
more than 24 h of hospitalization and showed quite
severe symptoms (not detailed in the reports). According
to the Ministry of Health, snakebites, nationally and
regardless of severity, appeared as one of the top five
causes of consultations in health facilities of first level,
with an annual average of 13,117 cases, after malaria (over
316,000 cases a year), acute respiratory infections (nearly
55,000 annual cases) and anemia (14,000 per year), but
before diarrhea (10,300 cases annually) coming in fifth.
The sex ratio was 1.1 (males/females) for patients aged
15 and older. The age distribution (Fig. 1) showed a
significantly higher incidence in patients older than five
years (χ2 = 1942; p < 10−5). The geographical distribution
is shown in Table 3 and Fig. 2. There was no significant
correlation between the incidence and population dens-
ity (r2 = 0.48; p > 0.065). Between 2010 and 2014, health
services reported 1,362 (1.2 %) deaths, 293 on average
each year. Annual mortality was between 1.13 and 2.06
deaths per 100,000 inhabitants (mean = 1.75). The aver-
age hospitalization rate was 66 %, not including 2014 for
which data were not yet consolidated.
Antivenom availability
In Burkina Faso, as occurs with other drugs and in accord-
ance with regulations, antivenom is sold by licensed
wholesalers. The number of vials sold between 2010 and
2014 was 5,738 with a total cost of US $ 539,055 (Table 4).
Two types of antivenom were available. The FAV-
Africa (Sanofi-Pasteur, France) and the polyvalent serum
West Africa EchiTAb-Plus-ICP (Instituto Clodomiro
Picado, Costa Rica). They respectively accounted for
Table 1 Annual incidence of snakebites in Burkina Faso,
2010–2014
Years Population Number of snakebites Incidence per 100,000
population
2010 15,730,977 22,662 144
2011 16,248,558 22,706 140
2012 16,779,207 23,343 139
2013 17,322,796 20,636 119
2014 17,880,386 24,779a 143a
Mean 16,792,385 22,337 136
aUnconsolidated data, not included in the calculation of the mean
Gampini et al. Journal of Venomous Animals and Toxins including Tropical Diseases  (2016) 22:10 Page 2 of 5
63.9 % and 36.1 % of sales and price transfer to public
and private structures were US$ 170 and 42, i.e., about
US$ 200 and 50 to the patients.
Less than 4 % of patients received antivenin treatment
over the past five years.
Discussion
The main objective of this study was to better estimate
the quantitative and qualitative demand for antivenom in
Burkina Faso [5]. Firstly, we wanted compare crude data
obtained from the epidemiological reporting system of the
Ministry of Health and the assessment based on the meta-
analysis from medical and scientific publications [4].
Secondly, our goal was to provide updated and accurate
data in order to define the necessary amount of antivenom
and the most relevant geographic location to offer it.
Like any retrospective study, our study presented some
limitations [6]. Reported data did not always contain rele-
vant and useful aspects for the implementation of
strategies for the prevention or management of snakebites.
Moreover, although the collection tools significantly
improved between 2010 and 2014, health statistics did not
provide useful information to health authorities regarding,
for example, seasonality of snakebites or treatment seeking
behavior of snakebite victims [1].
Another limitation was the lack of data from private
health centers. Most religious hospitals contributed in the
epidemiological reporting system and purchased anti-
venom from the wholesalers interviewed. In contrast, small
private clinics did not fit that framework. However, their
medical coverage was poor and they rarely treated snake-
bites, preferring to refer them to the nearest hospital.
Most epidemiological data confirmed the results ob-
tained elsewhere [4]. Snakebites occurred in active rural
populations, mainly men, although in Burkina Faso, it
seems that the number of women victims of snakebites
(47 % of adults bitten by a snake) was higher than
expected, as already stated by Somé et al. [7]. Indeed,
generally in Africa, the proportion of women bitten by a
snake is low [4]. The reasons are not known but one can
make the assumption that women are less often present
in areas at risk of bites. Indeed, snake populations vary
according to the biotopes and particularly type of planta-
tions, which may explain the difference, since men and
women are not working in the same field or at the same
hours [2, 7]. Another hypothesis is that women consulted
less frequently health centers than men in our study.
Although there is a higher incidence in rural areas,
particularly in the south and west of the country, there
was no significant correlation between the incidence of
bites and population density. Nevertheless, the incidence
of snakebites was significantly lower in highly urbanized
Table 2 Snakebite distribution according to the severity,
2010–2014
Years Outdoor
patient
Hospitalized
patients
Total
snakebites
Total deaths
2010 7,942 14,720 22,662 346
2011 7,235 15,471 22,706 307
2012 7,883 15,460 23,343 237
2013 7,543 13,093 20,636 283
2014 21,230a 3,549a 24,779a 189a
Mean 7,651 14,686 22,337 293
aUnconsolidated data, not included in the calculation of the mean
Fig. 1 Annual specific incidence of snakebites per 100,000 people according to the age group
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areas like the Center, where the capital Ouagadougou is
located, with an average annual incidence of snakebites
of 23 per 100,000 population (Table 3; Fig. 2) compared
to rural districts of South-West Burkina Faso where the
incidence can reach 300 per 100.000 population. This
suggests that the distribution of venomous snakes
involves populated areas including towns [8].
Although the incidence of snakebites was more than
the double of previous estimates, it is likely to remain
underrated [4]. For example, many patients preferred to
consult a traditional healer as indicated by a previous
study in the southwest of Burkina Faso in 2002 [7]. In
addition, several patients bitten by Elapidae snakes die
before reaching health centers due to a long delay
between the bite and admission to hospitals [9].
The available data did not allow the assessment of
envenomation severity, except when case fatality rate
reached 1.2 % of the bites (2.2 % of hospitalized patients).
Outpatients (51,833 patients between 2010 and 2014) were
supposed to have either asymptomatic bites or mild en-
venomation. In 2014, the number of snakebites increased
considerably (over 2,500 cases above the average of other
years), but also showed an inverted distribution between
outdoor patients and hospitalized patients. The 2014 data
have not yet been consolidated and we could not find any
explanation for the difference compared to other years. It
may result in a better management of snakebites in the
peripheral health facilities, perhaps through better distribu-
tion of antivenom, which resulted in avoiding referral to
the hospital. Note that the number of antivenom doses
used in 2014 was also higher than in other years. Unfortu-
nately, we do not know at what level of the health pyramid
these doses were administered. Moreover, even if their
number was higher, it did not reach the theoretical number
of doses corresponding to the number of registered cases.
Indeed, conditions, constraints and cost of hospitalization
were strongly dissuasive for patients with no or mild
envenomation or for those whose symptoms did not
force them to resort to hospitalization. Consequently,
it is possible to deduce from the number of hospital-
ized patients the minimal number of envenomed pa-
tients – on average 14,700 per year – who required
specific medical care, including antivenom. This could
be compared to the estimated annual incidence of
envenomation by Chippaux [4], which was half of the
present estimation (7,341 ± 1,260). In contrast, the es-
timated number of deaths by Chippaux [4] (343 ± 73)
was more close to our results, perhaps because the
reporting of deaths is more accurate than estimates of
snakebites.
The total number of sold antivenoms was very low
considering the incidence. Applying the treatment proto-
col recommended by the African Society of Venimology
would require more than 25,000 doses each year in
order to reduce 90 % of mortality and prevent many dis-
abilities by limb amputation following necrosis caused
by Viper bites [10]. However, very few patients (3.9 %)
Table 3 Geographical annual incidence of snakebites
(per 100,000 population)
Regions Population Density Incidence
Boucle du Mouhoun 1,700,424 50 184 ± 29
Cascades 674,553 36 205 ± 10
Centre 2,280,653 795 24 ± 2
Centre-Est 1,363,871 93 145 ± 82
Centre-Nord 1,438,149 74 114 ± 6
Centre-Ouest 1,407,877 65 171 ± 28
Centre-Sud 752,505 66 72 ± 9
Est 1,489,004 32 99 ± 1
Hauts-Bassins 1,806,821 71 164 ± 12
Nord 1,401,682 78 131 ± 91
Plateau-Central 818,568 95 148 ± 18
Sahel 1,176,768 33 81 ± 8
Sud-Ouest 740,128 45 295 ± 19
Total – Burkina Faso 17,051,002 62 130 ± 10
Fig. 2 Geographic distribution of snakebites in Burkina Faso (annual
mean incidence per 100,000 population)
Table 4 Evolution of the number of doses and cost of
antivenom, 2010–2014
Years Number of
doses
Overall cost
(US$)
Mean of dose
cost
2010 598 74,827 125
2011 846 105,859 125
2012 685 79,770 116
2013 1,100 82,896 75
2014 2,509 195,702 78
Mean of annual cost 1,148 107,811 104
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received antivenom treatment. Yet it was not clear how
many doses each patient received and it is possible that
some of them suffered complications (death, amputation,
permanent disability) as the result of uncontrolled
envenomation.
The reasons for the poor adherence to antivenom treat-
ment could be explained by their limited accessibility
because of numerous factors already described, namely:
high cost, lack of training of medical personnel, inaccurate
prediction of storage and distribution due to the absence
of relevant epidemiological data etc. [1, 3, 10]. The price
of antivenom was the same, regardless of the health insti-
tution that acquired it, resulting in a similar cost to all
health centers. However, as in most sub-Saharan coun-
tries, the cost of care is – so far – fully supported by the
patient and his family.
The high cost of antivenoms considerably limited
their access because the low income of the rural
population – the main victims of snakebites – pre-
vented them to adhere to an unaffordable treatment.
In the face of this situation, when negotiating the
prices of essential medicines with the Ministry of Health
and civil society, the public wholesaler (Centrale d’Achat
des Médicaments Essentiels Génériques et des Consom-
mables Médicaux du Burkina Faso, CAMEG) agreed in
2015 to cut the price of antivenom to US$ 3.4, since a
recent decision on health policy engages the government
to support the price difference through a subsidy. This
modification in the health policy should not change the
price of care between public and private health facilities
because all health facilities can provide antivenom
purchased from CAMEG. Now, patients buy the anti-
venom at 2,000 CFAF (about US $ 3), which represents
less than 5 % of its actual price, the rest is paid by the
government. This new policy should greatly facilitate
access to good quality care.
Conclusion
The notification of snakebites is operational in Burkina
Faso since 2010, which helped in clarifying and mapping
their incidence and mortality. With over 20,000 snake-
bites, of which nearly 15,000 envenomations, treated in
health facilities, and about 300 deaths reported every
year, this public health issue remains a concern. Rural
populations, particularly young active adults, are much
more exposed than urban people.
The underutilization of antivenom by health centers
is obvious but can be reverted. Knowing better the
actual demand and provided that health staff is ap-
propriately trained, it will be possible to switch the
vicious cycle of inaccessibility of antivenoms [1]. The
government subsidy will offer a realistic and probably
effective aid in this matter.
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